Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232

References

• Kalos MD, Li Y, Ludwig DL, et al. Elli Lilly Co., and Zymeworks Inc, England and United States, respectively. Checkpoint inhibitor bispecific antibodies. United State patent US2019010232. 2019 Jan 10.
   Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD L1 checkpoint. Immunity. 2018;48:434 52.
   Web of Science ®Google Scholar
• Monneur A, Goncalves A, Bertucci F. PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer. Bull Cancer. 2018;105(3):263–274.
   PubMed Web of Science ®Google Scholar
• Ma L, Lv J, Dong Y, et al. PD-L1 expression and its regulation in lung adenocarcinoma with ALK translocation. Interdiscip Sci. 2019;11(2):266–272.
   PubMed Web of Science ®Google Scholar
• He PX, Ma ZL, Han H, et al. Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer. Life Sci. 2020;242:117247.
   PubMed Web of Science ®Google Scholar
• Schütz F, Stefanovic S, Mayer L, et al., PD-1/PD-L1 pathway in breast cancer. Oncol Res Treat. 40(5): 294–297. 2017.
   PubMed Web of Science ®Google Scholar
• Payandeh Z, Khalili S, Somi MH, et al. PD-1/PD-L1 dependent immune response in colorectal cancer. J Cell Physiol. 2020. DOI:10.1002/jcp.29494.
   PubMed Web of Science ®Google Scholar
• Santini FC, Hellmann MD. PD-1/PD-L1 axis in lung cancer. Cancer J (Sudbury, Mass.). 2018;24(1): 15–19.
   PubMed Web of Science ®Google Scholar
• Markham A. Atezolizumab: first global approval. Drugs. 2016;76(12):1227–1232.
   PubMed Web of Science ®Google Scholar
• Syed YY. Durvalumab: first global approval. Drugs. 2017;77(12):1369–1376.
   PubMed Web of Science ®Google Scholar
• Kim ES. Avelumab: first global approval. Drugs. 2017;77(8):929–937.
   PubMed Web of Science ®Google Scholar
• Koppolu V, Vasigala VKR. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J Cancer Res Ther. 2018;14(6):1167–1175.
   PubMed Web of Science ®Google Scholar
• Poole RM. Pembrolizumab: first global approval. Drugs. 2014;74(16):1973–1981.
   PubMed Web of Science ®Google Scholar
• Liu J, Song N, Yang Y, et al. Beijing Hanmi Pharmaceutical Co., China. Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof. European patent EP3608341. 2020 Feb 12.
   Google Scholar
• Xu RH, Zhao H, Wei XL, et al. Phase Ia dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors. J clin oncol. 2020;38(15 suppl):3062.
   PubMedGoogle Scholar
• Gong B, Rennard R, Oliphant AF, et al. Compass therapeutics, United States. Multispecific binding constructs against checkpoint molecules and uses thereof. United States patent US2020181266. 2020 Jun 11.
   Google Scholar
• Yamauchi R, Araki T, Mitsuyama K, et al. The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenterol. 2018;18(1):135.
   PubMedGoogle Scholar
• Tada K, Kurihara Y, Myojo T, et al. Case report of nivolumab-related pneumonitis. Immunotherapy. 2017;9(4):313–318.
   PubMed Web of Science ®Google Scholar
• Kopecký J, Kubecek O, Geryk T, et al. Hepatic injury induced by a single dose of nivolumab-a case report and literature review. Klinicka onkologie: casopis Ceske a Slovenske onkologicke spolecnosti. 2019;32(2):133–138.
   PubMedGoogle Scholar
• Yamaguchi S, Morimoto R, Okumura T, et al. Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can J Cardiol. 2018;34(6):812–e1.
   PubMed Web of Science ®Google Scholar
• Zafar Z, Vogle C, Hudali T, et al. Nivolumab-associated acute demyelinating encephalitis: a case report and literature review. Clin Med Res. 2019;17(1–2):29–33.
   PubMed Web of Science ®Google Scholar
• Baroudjian B, Lourenco N, Pagès C, et al. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res. 2016;26(3):308–311.
   PubMed Web of Science ®Google Scholar
• Chen YL, Zhao J, Jia R, et al. Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review. Zhonghua Jie He He Hu Xi Za Zhi= Zhonghua Jiehe He Huxi Zazhi= Chinese Journal of Tuberculosis and Respiratory Diseases. 2017;40(10):736–743.
   PubMedGoogle Scholar
• Aivazian K, Long GV, Sinclair EC, et al. Histopathology of pembrolizumab-induced hepatitis: a case report. Pathology. 2017;49(7):789–792.
   PubMed Web of Science ®Google Scholar
• Martinez-Calle N, Rodriguez-Otero P, Villar S, et al. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica. 2018;103(7):e318.
   PubMed Web of Science ®Google Scholar
• Manam R, Martin JL, Gross JA, et al. Case reports of pembrolizumab-induced acute inflammatory demyelinating polyneuropathy. Cureus. 2018;10(9):e3371.
   PubMedGoogle Scholar
• González-Vázquez S, Riva-Onandía SDL, Echeveste JI, et al. Immune mediated colitis caused by lung cancer treatment with atezolizumab. Revista Española de Enfermedades Digestivas. 2017;109(12):863–864.
   PubMed Web of Science ®Google Scholar
• Hsu PC, Li SH, Yang CT. Recurrent pneumonitis induced by atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC patients who previously experienced anti-programmed death 1 immunotherapy-related pneumonitis. J Thorac Oncol. 2018;13(11):e227–e230.
   PubMed Web of Science ®Google Scholar
• Gupta R, Zaid S, Sayed A, et al. Atezolizumab induced myocarditis on a background of cardiac amyloidosis. Am J Ther. 2019;26(6):e795–e7.
   PubMed Web of Science ®Google Scholar
• Arakawa M, Yamazaki M, Toda Y, et al. Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review. eNeurologicalSci. 2019;14:49.
   PubMedGoogle Scholar
• Majeed M, Agrawa R, Gandhi S. Diarrhea in a patient receiving chemotherapy. Gastroenterology. 2019;157(6):1492–1493.
   PubMed Web of Science ®Google Scholar
• Tonk EH, van Lindert AS, Verhoeff JJ, et al. Acute-onset pneumonitis while administering the first dose of durvalumab. Case Rep Oncol. 2019;12(2):621–624.
   PubMed Web of Science ®Google Scholar
• Mahmood SS, Chen CL, Shapnik N, et al. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. Gynecol Oncol Rep. 2018;25:74–77.
   PubMed Web of Science ®Google Scholar
• Carrera W, Baartman BJ, Kosmorsky G. A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer. Neuro-Ophthalmology. 2017;41(3):140–143.
   PubMed Web of Science ®Google Scholar
• Brie V, Faure M, Garon J, et al. Drug-induced interstitial pneumonitis due to avelumab: A case report. Rev Mal Respir. 2018;35(9):978–982.
   PubMed Web of Science ®Google Scholar
• Berner AM, Sharma A, Agarwal S, et al. Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer. Eur J Cancer. 2018;101:287–290.
   PubMed Web of Science ®Google Scholar
• Reyes-Bueno JA, Rodriguez-Santos L, Serrano-Castro PJ. Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases. Rev Neurol. 2019;68(8):333–338.
   PubMed Web of Science ®Google Scholar